Health Condition 1: N201- Calculus of ureter
Conditions
Interventions
Intervention1: mirabegron: 50mg orally, once daily for 15 days
Control Intervention1: tamsulosin: 0.4mg orally, once daily before sleep for 14 days
Sponsors
Dr Josef B Pachikara
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who have underwent semirgid ureteroscopy with DJ stenting. 2. Only patients with uncomplicated ureteric calculi. 3 Patients aged 18 years to 60 years.
Exclusion criteria
Exclusion criteria: 1. Patients with growth in Urine culture or having symptomatic urinary tract infection. 2. Patients who may need bilateral stent insertion for acute obstruction / obstructive uropathy 3. Male patients with history of prostatic enlargement, prostatitis or prostatic cancer related lower urinary tract symptoms 4. Females with lower urinary tract symptoms related to any form of urinary incontinence, uterine/cervical/vaginal prolapse, or obstruction related to malignancy. 5. History of chronic or recent α-blocker or analgesic drug use were excluded. 6. Pregnancy, 7. Bleeding disorders, 8. Patients with concomitant other lower tract pathology like bladder cancer, bladder outlet obstruction with or without stones, urethral stricture. 9. Patients with simultaneous renal calculus. 10. Patients who underwent open surgery for ureteric calculi previously. 11. Patients not fulfilling inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effect of Tamsulosin and Mirabegron in ureteral stent related symptoms.Timepoint: 2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| to assess quality of life in patients taking tamsulosin and mirabegron for ureteral stent related symptoms as measured by USSQ quality of life scaleTimepoint: 2 weeks | — |
Countries
India
Contacts
Public ContactDr Josef B Pachikara
govt medical college trivandrum
Outcome results
None listed